Hangzhou Tigermed Consulting Co., Ltd (SHE:300347)

Market Cap	37.45B +7.6%
Revenue (ttm)	7.07B +8.7%
Net Income	771.46M +129.9%
EPS	0.92 +135.5%
Shares Out	855.14M
PE Ratio	50.36
Forward PE	35.38
Dividend	0.30 (0.65%)
Ex-Dividend Date	Jun 17, 2025

Volume	5,525,950
Average Volume	14,701,713
Open	46.00
Previous Close	46.11
Day's Range	44.99 - 46.40
52-Week Range	41.78 - 71.90
Beta	0.62
RSI	28.41
Earnings Date	Apr 29, 2026

About SHE:300347

Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality manag...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 11,130
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300347

Financial Performance

In 2025, SHE:300347's revenue was 6.83 billion, an increase of 3.48% compared to the previous year's 6.60 billion. Earnings were 887.89 million, an increase of 119.15%.